https://pmc.ncbi.nlm.nih.gov/articles/PMC11738990/
QT:{{”
Using AI-driven methodology, we generated INS018_055, a small-molecule TNIK inhibitor, which exhibits desirable drug-like properties and anti-fibrotic activity across different organs in vivo through oral, inhaled or topical administration…. Its safety and tolerability as well as pharmacokinetics were validated in a randomized,
double-blinded, placebo-controlled phase I clinical trial
(NCT05154240) involving 78 healthy participants.
“}}
Ren, F., Aliper, A., Chen, J., Zhao, H., Rao, S., Kuppe, C., Ozerov, I. V., Zhang, M., Witte, K., Kruse, C., Aladinskiy, V., Ivanenkov, Y., Polykovskiy, D., Fu, Y., Babin, E., Qiao, J., Liang, X., Mou, Z., Wang, H., . . . Zhavoronkov, A. (2024). A small-molecule TNIK inhibitor targets fibrosis in preclinical and clinical models. Nature Biotechnology, 43(1), 63–75.
https://doi.org/10.1038/s41587-024-02143-0
